Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395455 | 0.75 | RXRA (0.49) | MAPTCYP19A1CTDSP1TDP1ALDH1A1 | |
| SCHEMBL7395451 | 0.75 | RXRA (0.49) | MAPTCYP19A1CTDSP1TDP1ALDH1A1 | |
| SCHEMBL5479417 | 0.75 | RXRA (0.49) | MAPTCYP19A1CTDSP1TDP1ALDH1A1 | |
| SCHEMBL6991841 | 0.74 | CYP19A1 (0.40) | MAPTCYP19A1TBXAS1CTDSP1TDP1 | |
| SCHEMBL6991846 | 0.74 | CYP19A1 (0.40) | MAPTCYP19A1TBXAS1CTDSP1TDP1 | |
| SCHEMBL7920355 | 0.73 | CTDSP1 (0.38) | MAPTCTDSP1TDP1ESR2ALDH1A1 | |
| SCHEMBL12550714 | 0.73 | RXRA (0.53) | MAPTCYP19A1ESR2CYP2C19HPGD | |
| SCHEMBL21538739 | 0.72 | RXRA (0.49) | MAPTCTDSP1TDP1ESR2ALDH1A1 | |
| SCHEMBL8485089 | 0.72 | CTDSP1 (0.40) | MAPTCTDSP1TDP1ESR2ALDH1A1 | |
| SCHEMBL14563379 | 0.72 | MAOA (0.47) | ESR2CYP2C19CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505739-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865701-B2 | Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2398789-B1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| WO-2010094242-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038490-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | MAPT 133/4885PKM 2590/4885CYP19A1 507/4885 |
| US-20110306595-A1 | SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | MAPT 133/4885PKM 2590/4885CYP19A1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.